Biotika (1BSL01AE) Stock Overview
Operates as a pharmaceutical manufacturing company in Slovakia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
1BSL01AE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biotika a.s. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10.00 |
| 52 Week High | €16.00 |
| 52 Week Low | €7.00 |
| Beta | 0.0085 |
| 1 Month Change | -4.76% |
| 3 Month Change | 42.86% |
| 1 Year Change | -50.00% |
| 3 Year Change | -56.52% |
| 5 Year Change | -67.74% |
| Change since IPO | -98.73% |
Recent News & Updates
Investors Still Aren't Entirely Convinced By Biotika a.s.'s (BSSE:1BSL01AE) Revenues Despite 29% Price Jump
Oct 31
Is Biotika (BSSE:1BSL01AE) A Risky Investment?
Oct 29Improved Revenues Required Before Biotika a.s. (BSSE:1BSL01AE) Stock's 33% Jump Looks Justified
Dec 14Recent updates
Investors Still Aren't Entirely Convinced By Biotika a.s.'s (BSSE:1BSL01AE) Revenues Despite 29% Price Jump
Oct 31Is Biotika (BSSE:1BSL01AE) A Risky Investment?
Oct 29Improved Revenues Required Before Biotika a.s. (BSSE:1BSL01AE) Stock's 33% Jump Looks Justified
Dec 14Biotika a.s. (BSSE:1BSL01AE) Stock Catapults 55% Though Its Price And Business Still Lag The Industry
Oct 13Biotika a.s.'s (BSSE:1BSL01AE) Revenues Are Not Doing Enough For Some Investors
Aug 21Should You Buy Biotika a.s. (BSSE:1BSL01AE) For Its Dividend?
Nov 30Shareholder Returns
| 1BSL01AE | SK Pharmaceuticals | SK Market | |
|---|---|---|---|
| 7D | 5.3% | 0.8% | -0.1% |
| 1Y | -50.0% | -3.4% | 17.2% |
Return vs Industry: 1BSL01AE underperformed the SK Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 1BSL01AE underperformed the SK Market which returned 17.1% over the past year.
Price Volatility
| 1BSL01AE volatility | |
|---|---|
| 1BSL01AE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in SK Market | 9.8% |
| 10% least volatile stocks in SK Market | 2.4% |
Stable Share Price: 1BSL01AE's share price has been volatile over the past 3 months compared to the SK market.
Volatility Over Time: Insufficient data to determine 1BSL01AE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1953 | 150 | n/a | www.biotika.sk |
Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally. The company offers active pharmaceutical ingredients (API), including phenoxymethylpenicillin calcium, phenoxymethylpenicillin potassium, phenoxymethylpenicillin potassium granulated, and polymyxin B sulfate (non-sterile) substances; and pharmaceutical preparations for the human and veterinary applications. It is also involved in the contract manufacture of APIs comprising Gramicidin S hydrochlorid (non-sterile) and L-CYSTINE substances; and antibiotics.
Biotika a.s. Fundamentals Summary
| 1BSL01AE fundamental statistics | |
|---|---|
| Market cap | €7.00m |
| Earnings (TTM) | -€2.86m |
| Revenue (TTM) | €18.66m |
Is 1BSL01AE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BSL01AE income statement (TTM) | |
|---|---|
| Revenue | €18.66m |
| Cost of Revenue | €14.37m |
| Gross Profit | €4.29m |
| Other Expenses | €7.15m |
| Earnings | -€2.86m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.08 |
| Gross Margin | 22.99% |
| Net Profit Margin | -15.31% |
| Debt/Equity Ratio | 11.1% |
How did 1BSL01AE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 23:25 |
| End of Day Share Price | 2025/12/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotika a.s. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.